This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Biomarker Research for Personalized Medicine

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2013 by Jae-Gook Shin, Inje University.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Jae-Gook Shin, Inje University Identifier:
First received: December 6, 2011
Last updated: May 30, 2013
Last verified: May 2013

The aim of this study :

  1. Through the study of genes of protein, transporter, translator and epigenome investigating the effect of anti-cancer treatment or the key factor of the MDR (Multidrug resistance) on the blood cancer patients who are under the anti-cancer sork treatment
  2. Giving a service of anticancer medicine therapeutic drug monitoring (TDM) and genotyping

Hematologic Neoplasms

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Biomarker Research for Personalized Medicine in Blood Cancer Patient

Further study details as provided by Jae-Gook Shin, Inje University:

Biospecimen Retention:   Samples With DNA
whole blood

Estimated Enrollment: 1000
Study Start Date: April 2009

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
healthy volunteers

Inclusion Criteria:

  • Korean
  • Clinical diagnosis of Hematologic neoplasms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01488591

Contact: Jae Gook Shin, M.D.,Ph.D. 82-51-890-6709

Korea, Republic of
Inje University Recruiting
Busan, Korea, Republic of, 614-735
Contact: Jae Gook Shin, M.D., Ph.D.    82-51-890-6709   
Sponsors and Collaborators
Inje University
  More Information

Responsible Party: Jae-Gook Shin, Department of Pharmacology and Pharmacogenomics Research Center, Inje University Identifier: NCT01488591     History of Changes
Other Study ID Numbers: 09-029
Study First Received: December 6, 2011
Last Updated: May 30, 2013

Additional relevant MeSH terms:
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases processed this record on August 18, 2017